Key Facts

Invested since 2019
Based in Saxony

About the company

DyNAbind is offering innovative drug discovery products and services based on its proprietary Dynamic DNA-Encoded Library (D-DEL) technology platform. With D-DEL, DyNAbind can simultaneously screen hundreds of millions of compounds against a target protein. Follow-up hit triage is also rapid, thanks to the Binding Profiler system for hit validation. Altogether, DyNAbind’s platform delivers higher-quality, more relevant medicinal chemistry starting points at about 10 times the speed of conventional approaches.

Do you want to

know more about this company?

Zum Artikel

Dr. Laura Pedroza Senior Investment Manager

Dr. Laura PedrozaSenior Investment Manager

DyNAbind in the news

Zum Artikel

News

7. May 2019

Drug discovery technology start-up DyNAbind secures seed financing

More startups from Life Sciences